A Multicenter Study to Evaluate Efficacy and Safety
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Glycemic Variability of Combination Therapies in T2DM
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Locations
Other Locations
Republic of Korea
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
RECRUITING
Seoul
Contact Information
Primary
Saemi Kang
kangsm@jwhealthcare.com
82-2-840-6902
Time Frame
Start Date: 2025-10-29
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 178
Treatments
Experimental: Experimental
Empagliflozin/Metformin + Anagliptin
Active_comparator: Active Comparator
Metformin + Empagliflozin/Linagliptin
Related Therapeutic Areas
Sponsors
Leads: JW Pharmaceutical